Last updated: 29 June 2020 at 7:37pm EST

Patrick Cambridge Equities,... Net Worth




The estimated Net Worth of Patrick Cambridge Equities,... is at least $772 Million dollars as of 29 June 2020. Patrick Equities owns over 3,710,000 units of NantKwest Inc stock worth over $771,661,868 and over the last 9 years Patrick sold NK stock worth over $0.

Patrick Equities NK stock SEC Form 4 insiders trading

Patrick has made over 4 trades of the NantKwest Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Patrick bought 3,710,000 units of NK stock worth $44,965,200 on 29 June 2020.

The largest trade Patrick's ever made was buying 3,710,000 units of NantKwest Inc stock on 29 June 2020 worth over $44,965,200. On average, Patrick trades about 860,108 units every 253 days since 2015. As of 29 June 2020 Patrick still owns at least 23,750,750 units of NantKwest Inc stock.

You can see the complete history of Patrick Equities stock trades at the bottom of the page.



Insiders trading at NantKwest Inc

Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin und Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.



What does NantKwest Inc do?

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.



What does NantKwest Inc's logo look like?

NantKwest Inc logo

Complete history of Patrick Equities stock trades at NantHealth Inc und NantKwest Inc

Datum
#
Unternehmen
Insider
Trans.
Transaktion
Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
29 Jun 2020 Patrick Cambridge Equities,...
Vorsitzende und CEO
Kauf 3,710,000 $12.12 $44,965,200
29 Jun 2020
23,750,750
21 Mar 2019 Patrick Cambridge Equities,...
Vorsitzende und CEO
Optionausübung 1,851,500 $2.20 $4,073,300
21 Mar 2019
20,040,750
11 Jul 2018 Patrick Cambridge Equities,...
Vorsitzende und CEO
Optionausübung 9,257 $1.62 $14,996
11 Jul 2018
40,565,814
21 Aug 2015 Patrick Cambridge Equities,...
Vorsitzende und CEO
Kauf 450,000 $23.00 $10,350,000
21 Aug 2015
41,016,557


NantKwest Inc executives and stock owners

NantKwest Inc executives and other stock owners filed with the SEC include: